文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

整合多组学分析揭示ARDS宿主反应图谱并建立血清蛋白组合用于早期预后预测

Integrative multi-omics analysis unravels the host response landscape and reveals a serum protein panel for early prognosis prediction for ARDS.
PubMed 文献 · Crit Care · 2024-07-02
一句话结论多中心观察性研究:基于血清蛋白的预测模型在发现队列和外部验证队列中均优于临床模型,用于预测ARDS患者28天预后。

该研究为多中心观察性研究,对ARDS初始阶段患者、疾病对照和健康对照的血清进行4D-DIA蛋白质组学和全局代谢组学分析。在发现队列(130例成人ARDS患者、33例疾病对照、33例健康对照)中,通过LASSO、倍数变化分析和Boruta算法筛选28天预后生物标志物,并在外部验证队列(183例患者)中用PRM靶向质谱验证。发现36种候选蛋白,其中8种蛋白(VCAM1、LDHB、MSN、FLG2、TAGLN2、LMNA、MBL2、LBP)在验证队列中显示显著一致性。基于蛋白的模型在发现队列(AUC 0.893 vs 0.784,Delong检验P<0.001)和验证队列(AUC 0.802 vs 0.738,Delong检验P=0.008)中预测准确性均优于临床模型。

要点

  • 在130例成人ARDS患者(平均年龄72.5岁,74.6%男性)中发现36种候选蛋白生物标志物,用于预测28天预后。
  • 8种蛋白(VCAM1、LDHB、MSN、FLG2、TAGLN2、LMNA、MBL2、LBP)在183例独立验证队列(平均年龄72.6岁,73.2%男性)中经PRM靶向质谱验证显示显著一致性。
  • 基于蛋白的预测模型在发现队列中AUC为0.893,优于临床模型的0.784(Delong检验P<0.001)。
  • 在验证队列中,蛋白模型AUC为0.802,仍优于临床模型的0.738(Delong检验P=0.008)。
  • 通路分析提示鞘脂信号通路上调是ARDS病理机制的关键 contributor,MAP2K1为枢纽蛋白,代谢物S1P与ARDS及其预后密切相关。

适用人群与场景

  • 纳入初始阶段ARDS成人患者(发现队列130例,平均年龄72.5岁,74.6%男性;验证队列183例,平均年龄72.6岁,73.2%男性),并设疾病对照组(33例)和健康对照组(33例)。

研究设计与关键结果

  • 研究类型:多中心观察性研究;发现队列130例成人ARDS患者、33例疾病对照和33例健康对照,外部验证队列183例患者。
  • 在发现队列中,通过LASSO、倍数变化分析和Boruta算法鉴定出36种候选蛋白生物标志物,其中8种蛋白(VCAM1、LDHB、MSN、FLG2、TAGLN2、LMNA、MBL2、LBP)在独立验证队列中经PRM靶向质谱验证显示显著一致性。
  • 基于蛋白的预测模型在发现队列中AUC为0.893,临床模型AUC为0.784(Delong检验P<0.001);在验证队列中蛋白模型AUC为0.802,临床模型AUC为0.738(Delong检验P=0.008)。
  • 通路分析显示鞘脂信号通路上调是ARDS病理机制的关键 contributor,MAP2K1为枢纽蛋白,代谢物鞘氨醇-1-磷酸(S1P)与ARDS及其预后密切相关;死亡ARDS患者中造血细胞谱系和钙信号通路下调,而未折叠蛋白反应和糖酵解上调,GAPDH和ENO1在蛋白互作网络中交互度最高。

证据类型、等级与局限

  • 证据类型:多中心观察性研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该多组学研究揭示了ARDS的潜在生物学机制和治疗靶点,并建立了经验证的预测模型用于ARDS不良预后预测,为ARDS患者的预后提供了有价值的见解。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The multidimensional biological mechanisms underpinning acute respiratory distress syndrome (ARDS) continue to be elucidated, and early biomarkers for predicting ARDS prognosis are yet to be identified.

METHODS: We conducted a multicenter observational study, profiling the 4D-DIA proteomics and global metabolomics of serum samples collected from patients at the initial stage of ARDS, alongside samples from both disease control and healthy control groups. We identified 28-day prognosis biomarkers of ARDS in the discovery cohort using the LASSO method, fold change analysis, and the Boruta algorithm. The candidate biomarkers were validated through parallel reaction monitoring (PRM) targeted mass spectrometry in an external validation cohort. Machine learning models were applied to explore the biomarkers of ARDS prognosis.

RESULTS: In the discovery cohort, comprising 130 adult ARDS patients (mean age 72.5, 74.6% male), 33 disease controls, and 33 healthy controls, distinct proteomic and metabolic signatures were identified to differentiate ARDS from both control groups. Pathway analysis highlighted the upregulated sphingolipid signaling pathway as a key contributor to the pathological mechanisms underlying ARDS. MAP2K1 emerged as the hub protein, facilitating interactions with various biological functions within this pathway. Additionally, the metabolite sphingosine 1-phosphate (S1P) was closely associated with ARDS and its prognosis. Our research further highlights essential pathways contributing to the deceased ARDS, such as the downregulation of hematopoietic cell lineage and calcium signaling pathways, contrasted with the upregulation of the unfolded protein response and glycolysis. In particular, GAPDH and ENO1, critical enzymes in glycolysis, showed the highest interaction degree in the protein-protein interaction network of ARDS. In the discovery cohort, a panel of 36 proteins was identified as candidate biomarkers, with 8 proteins (VCAM1, LDHB, MSN, FLG2, TAGLN2, LMNA, MBL2, and LBP) demonstrating significant consistency in an independent validation cohort of 183 patients (mean age 72.6 years, 73.2% male), confirmed by PRM assay. The protein-based model exhibited superior predictive accuracy compared to the clinical model in both the discovery cohort (AUC: 0.893 vs. 0.784; Delong test, P < 0.001) and the validation cohort (AUC: 0.802 vs. 0.738; Delong test, P = 0.008).

INTERPRETATION: Our multi-omics study demonstrated the potential biological mechanism and therapy targets in ARDS. This study unveiled several novel predictive biomarkers and established a validated prediction model for the poor prognosis of ARDS, offering valuable insights into the prognosis of individuals with ARDS.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Lin M, Xu F, Sun J, et al. Integrative multi-omics analysis unravels the host response landscape and reveals a serum protein panel for early prognosis prediction for ARDS. Crit Care. 2024. PMID: 38956604. doi:10.1186/s13054-024-05000-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。